Investment
Features
FeesSafety
Academy
More
Pluang+

Compare iShares MSCI Taiwan ETF (EWT) vs Cassava Sciences Inc (FLNA) Price & Performance

iShares MSCI Taiwan ETFTrade
Cassava Sciences IncTrade

Price performance (Past 24H)

Key statistics

iShares MSCI Taiwan ETF vs Cassava Sciences Inc — how do they compare? iShares MSCI Taiwan ETF trades at $100.25, while Cassava Sciences Inc trades at $1.1 (market cap $53.14M). The key difference: iShares MSCI Taiwan ETF is trading nearer its 52-week high, Cassava Sciences Inc nearer its low. Which is the better fit depends on your goals.

EWTFLNA
Sector
Broad Market / FactorHealth
52-Week High
$111.53$4.64
52-Week Low
$58.05$1.09
Market Cap
$53.14M
Enterprise Value
-$33.43M

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

iShares MSCI Taiwan ETF

The iShares MSCI Taiwan ETF (EWT) trades at $100.08, down 1.77% on the day, consolidating after a significant rally that saw the fund more than double over the past year. Technical indicators show a neutral overall signal with mixed moving average and oscillator readings, while the fund remains strategically positioned at the center of the global AI infrastructure surge through its heavy exposure to Taiwan's semiconductor sector, led by TSMC.

The outlook for EWT is balanced between strong fundamental tailwinds from AI-driven semiconductor demand and significant geopolitical risks related to Taiwan-China tensions. While the fund offers concentrated exposure to a critical technology supply chain, stretched valuations and potential currency headwinds create near-term uncertainty for investors.

Cassava Sciences Inc

FLNA trades at $1.06, down 2.75% today, with a bearish technical signal from moving averages but neutral oscillators. The stock shows a low P/B of 0.78, yet profitability metrics are negative, including a -79.59% ROE and -$90.97M net income for 2025. Recent Q1 2026 earnings beat expectations, and analyst consensus is 66.7% buy. News highlights Q1 financial results and a scientific presentation on TSC-related epilepsy therapies.

Outlook remains speculative due to persistent losses and negative cash flows, offset by strong analyst support and recent earnings beats. Key risks include funding needs for drug development and competitive pressures, while potential upside hinges on clinical progress in TSC-related epilepsy treatments.

Returns comparison

Trailing returns across standard periods

About iShares MSCI Taiwan ETF

EWT tracks the MSCI Taiwan 25/50 Index, providing targeted exposure to large and mid-cap companies in Taiwan. It is heavily concentrated in the information technology sector, serving as a liquid instrument for investors seeking a single-country view of Taiwan's export-oriented and tech-driven economy.

Read more on EWT

About Cassava Sciences Inc

Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease

Read more on FLNA